AI CuratorAI-generated
Research summary · AI summary · not yet reviewedHuman studyInterventionalTrial registry record – peer review not applicable
Autologous Haemopoietic Stem Cell Transplantation in Human Subjects with Refractory MS
A study is planned where 20 human subjects with refractory multiple sclerosis (MS) will undergo autologous haemopoietic stem cell transplantation, with a follow-up period of three years to evaluate MS activity-free survival.
- Tags
- #MSResearch
- Most relevant to
- —
- Source
- Read original source
This plain-English summary was written by AI from a trial registry record and may contain errors. It is not medical advice. Read the original study and talk to your MS team before making decisions about treatment.
- Human efficacy
- Not yet assessed
- Mechanism
- Not yet assessed
- Evidence strength
- Not yet assessed
- Outcome
- Not yet assessed
Why it matters
This research represents a potential approach to treating refractory MS, aiming to assess the effectiveness of stem cell treatment in improving patient outcomes.
What this does not prove
No results are available yet, and the study has not started recruiting participants, so findings cannot be derived from this data.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Interventional
- Participants / samples
- 20 · basis not reported
- Randomised
- Not applicable
- Controlled
- Not applicable
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- Not reported
- Evidence reviewed
- Trial registry record
- Regulatory approval
- No
- Research areas
- Not classified
Original sources
Supporting passages (13)
study phase"phases": [ "NA" ]
study design"studyType": "INTERVENTIONAL"
subjects"conditions": [ "Multiple Sclerosis" ]
sample size"count": 20, "type": "ESTIMATED"
randomized"allocation": "NA"
controlled"allocation": "NA"
peer reviewedNo results are posted.
regulatory approval"isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false
intervention"name": "Autologous haemopoietic stem cell transplantation"
primary endpoint"measure": "3 year MS activity free survival"
follow up"timeFrame": "3 year follow-up post transplant"
findings"description": "Patients will undergo stem cell transplantation for the treatment of refractory MS"
limitationsNo results are posted. Planned enrolment and endpoints are not findings.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.